SENOLYTICS – A DISCOVERY THAT COULD TRANSFORM THE COURSE OF AGING AND CHRONIC DISEASES
Abstract
Senescent cells play a pivotal role in the progression of age-related diseases by promoting chronic inflammation and disrupting tissue function through the secretion of senescence-associated secretory phenotype (SASP) factors. Senolytics, a novel class of therapeutic agents, enable the selective elimination of these cells or the attenuation of their deleterious effects, offering a potential avenue to enhance healthspan. Preclinical studies and early clinical trials indicate that senolytics can improve cardiovascular function, metabolism, and physical performance, while demonstrating an acceptable safety profile. This review presents the mechanisms of action of senolytics, the current state of research, and their potential applications in metabolic, neurodegenerative, and cardiovascular diseases.
References
Chaib S, Tchkonia T, Kirkland JL. Cellular senescence and senolytics: the path to the clinic. Nat Med. 2022;28(8):1556 1568.
Lin YF, Wang LY, Chen CS, et al. Cellular senescence as a driver of cognitive decline triggered by chronic unpredictable stress. Neurobiol Stress. 2021;15:100341.
Martinez-Zamudio RI, Robinson L, Roux PF, et al. SnapShot: Cellular Senescence Pathways. Cell. 2017;170:816 816.e1.
Zhou Y, et al. Senolytics alleviate the degenerative disorders of temporomandibular joint in old age. Aging Cell. 2022;21:e13394.
Guan J, Li T, Ma F, et al. DNA damage-dependent mechanisms of ionizing radiation-induced cellular senescence. PeerJ. 2025;13:e20087.
Gasek NS, Kuchel GA, Kirkland JL, et al. Strategies for targeting senescent cells in human disease. Nat Aging. 2021;1(10):870 879.
Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: A focus on protein modifications. Genes Dev. 2011;25:409 433.
Rossiello F, Herbig U, Longhese MP, et al. Irreparable telomeric DNA damage and persistent DDR signalling as a shared causative mechanism of cellular senescence and ageing. Curr Opin Genet Dev. 2014;26:89 95.
White RR, Milholland B, de Bruin A, et al. Controlled induction of DNA double-strand breaks in the mouse liver induces features of tissue ageing. Nat Commun. 2015;6.
Watts FZ. Repair of DNA Double-Strand Breaks in Heterochromatin. Biomolecules. 2016;6(4):47.
Chiruvella KK, Liang Z, Wilson TE, et al. Repair of double-strand breaks by end joining. Cold Spring Harb Perspect Biol. 2013;5:a012757.
Doksani Y. The Response to DNA Damage at Telomeric Repeats and Its Consequences for Telomere Function. Genes (Basel). 2019;10(4):318.
Mateos-Gomez PA, Gong F, Nair N, et al. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. Nature. 2015;518(7538):254 257.
Wang C, Jurk D, Maddick M, et al. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell. 2009;8:311 323.
Rodier F, Munoz DP, Teachenor R, et al. DNA-SCARS: Distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci. 2011;124:68 81.
Fumagalli M, Rossiello F, Mondello C, et al. Stable cellular senescence is associated with persistent DDR activation. PLoS ONE. 2014;9:e110969.
Benarroch-Popivker D, Pisano S, Mendez-Bermudez A, et al. TRF2-mediated control of telomere DNA topology as a mechanism for chromosome-end protection. Mol Cell. 2016;61:274 286.
Fumagalli M, Rossiello F, Clerici M, et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol. 2012;14(4):355 365.
De Lange T. Shelterin: The protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100 2110.
Zhang L, Pitcher LE, Yousefzadeh MJ, et al. Cellular senescence: a key therapeutic target in aging and diseases. J Clin Invest. 2022;132(15):e158450.
Franceschi C, Garagnani P, Parini P, et al. Inflammaging and ‘garb-aging’. Front Immunol. 2019;10:2787.
Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Cell. 2016;165(7):1556 1567.
Childs BG, Baker DJ, Kirkland JL, et al. Senescence and apoptosis: dueling or complementary cell fates? J Clin Invest. 2014;124(4):1621 1630.
van Deursen JM. The role of senescent cells in aging. Nature. 2014;509(7501):439 446.
Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518 536.
Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644 658.
Fuhrmann-Stroissnigg H, Niedernhofer LJ, Robbins PD. Hsp90 inhibitors as senolytic drugs to extend healthy aging. Cell Cycle. 2018;17(9):1048 1055.
Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the Bcl-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955 963.
Rad AN, et al. Current senolytics: Mode of action, efficacy and limitations, and their future. Aging Cell. 2024;23:112 130.
Wissler Gerdes EO, Zhu Y, Tchkonia T, et al. Discovery, development, and future application of senolytics: theories and predictions. FEBS J. 2020;287(12):2418 2427.
Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246 1256.
Yosef R, Pilpel N, Tokarsky Amiel R, et al. Directed elimination of senescent cells by inhibition of BCL W and BCL XL. Nat Commun. 2016;7:11190.
Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15(3):428 435.
Childs BG, Durik M, Baker DJ, et al. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015;21(12):1424 1435.
Lelarge V, Capelle R, Oger F, et al. Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients’ treatment. npj Aging. 2024;1:1 12.
Stojanović SD, et al. Anti-senescence therapies: a new concept to address cardiovascular disease. Cardiovasc Res. 2025;121:730 745.
Saliev T, Singh PB. Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions. Biomolecules. 2025;15:860.
Matsubayashi S, et al. Drugs against metabolic diseases as potential senotherapeutics. Front Endocrinol. 2023;14:1079626.
Luis C, et al. Nutritional senolytics and senomorphics: Implications to aging and age-related diseases. Front Nutr. 2022;9:958563.
Fuhrmann-Stroissnigg H, Ling YY, Zhao J, et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun. 2017;8:422.
Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label pilot study. EBioMedicine. 2019;40:554 563.
Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Results from a pilot study using dasatinib and quercetin in patients with chronic kidney disease. Aging Cell. 2019;18(2):e13038.
Millar CL, Iloputaife I, Baldyga K, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer’s disease. EBioMedicine. 2025;113:105612.
Millar CL, Iloputaife I, Baldyga K, et al. Rationale and design of STAMINA: Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging — a geroscience feasibility study. Transl Med Aging. 2023;7:109 117.
Millar CL, Iloputaife I, et al. Senolytic effects on cognition, mobility, and biomarkers in older adults with MCI and slow gait: a pilot study (STAMINA). Innovation Aging. 2024;8(Supplement_1):1157.
Jia K, Dai Y, Liu A, et al. Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice. J Cardiovasc Pharmacol. 2020;76(4):452 460.
Walaszczyk A, Dookun E, Redgrave R, et al. Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. Aging Cell. 2019;18(3):e12945.
Lérida-Viso A, Estepa-Fernández A, Morellá-Aucejo Á, et al. Pharmacological senolysis reduces doxorubicin-induced cardiotoxicity and improves cardiac function in mice. Pharmacol Res. 2022;183:106356.
Zhai P, Sadoshima J. Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart. J Cardiovasc Aging. 2024;4:18.
Owens WA, Walaszczyk A, Spyridopoulos I, et al. Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls. Mech Ageing Dev. 2021;198:111540.
McHugh D, Gil J. Senescence and aging: Does clearance of senescent cells do more harm than good? Ageing Res Rev. 2018;50:123 133.
Roos CM, Zhang B, Palmer AK, Ogrodnik M, Pirtskhalava T, Thalji NM, et al. Senolytic therapies for cardiovascular aging: tackling fibrosis and metabolic dysfunction. Nat Rev Cardiol. 2024;21(7):405–22.
de Oliveira Silva T, Lunardon G, Lino CA, et al. Senescent cell depletion alleviates obesity-related metabolic and cardiac disorders. Mol Metab. 2025;91:102065.
Sikora E, Bielak-Zmijewska A, Dudkowska M, et al. Cellular Senescence in Brain Aging. Front Aging Neurosci. 2021;13:646924.
Rim C, You MJ, Nahm M, et al. Emerging role of senescent microglia in brain aging-related neurodegenerative diseases. Transl Neurodegener. 2024;13:10.
Ichim TE, Ramos RA, Rath A, et al. Reversing coma by senolytics and stem cells: the future is now. J Transl Med. 2025;23:1060.
Islam MT, Tuday E, Allen S, et al. Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age. Aging Cell. 2023;22(2):e13767.
Yang J, Zhang H, Gu Z, et al. Dasatinib and Quercetin alleviate type 2 diabetic osteoporosis by regulating serum metabolite and gut microbiome. Front Microbiol. 2025;16:1631082.
Maurer S, Kirsch V, Ruths L, et al. Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro anabolic mediators. Aging Cell. 2024;24(1):e14361.
Zhu X, Zhang C, Liu L, et al. Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway. Int J Mol Med. 2024;53(3):26.
Schweiger A, Diniz B, Nicol G, et al. Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders. F1000Res. 2025;13:1072.
Views:
0
Downloads:
0
Copyright (c) 2026 Kamil Kania, Marcel Bobiński, Zuzanna Wieczorek, Wiktoria Skowron, Justyna Bartol, Aleksandra Sosińska, Justyna Rajczyk, Monika Wiczuk–Wiczewska, Adam Szymczak, Tomasz Lepich
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
